title: Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
abstract: Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on "Antibodies to watch" in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for antibody discovery and engineering from synthetic and in vivo libraries and on computational antibody design.
authors.affiliation: a Genmab; Utrecht, the Netherlands and Leiden University Medical Center ; Leiden , the Netherlands.
authors.forename: Paul W H I
authors.initials: PW
authors.lastname: Parren
authors.affiliation: b The Scripps Research Institute ; La Jolla , CA USA.
authors.forename: Dennis R
authors.initials: DR
authors.lastname: Burton
authors.affiliation: c Los Alamos National Laboratory ; Los Alamos , NM USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Bradbury
authors.affiliation: d Huston BioConsulting, LLC ; Newton Lower Falls , MA USA.
authors.forename: James S
authors.initials: JS
authors.lastname: Huston
authors.affiliation: e Genentech, Inc.. ; South San Francisco , CA USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Carter
authors.affiliation: f AbbVie ; Worcester , MA USA.
authors.forename: Trudi
authors.initials: T
authors.lastname: Veldman
authors.affiliation: g University College London ; London , UK.
authors.forename: Kerry A
authors.initials: KA
authors.lastname: Chester
authors.affiliation: h Panorama Research Institute and Velocity Pharmaceutical Development ; South San Francisco , CA USA.
authors.forename: James W
authors.initials: JW
authors.lastname: Larrick
authors.affiliation: i EnGen Bio, Inc.. ; San Mateo , CA USA.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Alfenito
authors.affiliation: j Simon Fraser University ; Burnaby , BC Canada.
authors.forename: Jamie K
authors.initials: JK
authors.lastname: Scott
authors.affiliation: k Georgetown University Medical Center ; Washington, DC USA.
authors.forename: Louis M
authors.initials: LM
authors.lastname: Weiner
authors.affiliation: l Viventia Bio, Inc.. ; Philadelphia , PA USA.
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Adams
authors.affiliation: m Reichert Biotechnology Consulting LLC ; Framingham , MA USA.
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
mesh_terms: D018033:Antibodies, Bispecific / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology* / Q000627:therapeutic use; D007141:Immunoglobulin Fc Fragments / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D015202:Protein Engineering / Q000379:methods*; D057170:Translational Research, Biomedical / Q000379:methods
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments
keywords: antibody engineering; antibody repertoire; antibody-drug conjugates; bispecific antibodies; computational design; next-generation sequencing; reproducibility